 | • レポートコード：PMR20MY090 • 出版社/出版日：Persistence Market Research / 2020年1月24日 • レポート形態：英文、PDF、176ページ • 納品方法：Eメール • 産業分類：生命科学&トランスフォーメーショナルヘルス |
| Individual User（1名用） | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Multi User（5名用） | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Corporate User（企業用） | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、世界の自家ワクチン市場について調査・分析し、エグゼクティブサマリー、市場概要、市場動向、市場状況、市場需要分析及び予測、市場背景、北米、中南米、ヨーロッパ、南アジア市場分析などを含め、以下の構成でお届け致します。 ・世界の自家ワクチン市場：エグゼクティブサマリー ・世界の自家ワクチン市場：概要 ・世界の自家ワクチン市場：動向 ・世界の自家ワクチン市場：状況 ・世界の自家ワクチン市場：需要分析及び予測 ・世界の自家ワクチン市場：背景 ・北米の自家ワクチン市場：分析及び予測 ・中南米の自家ワクチン市場：分析及び予測 ・ヨーロッパ自家ワクチン市場：分析及び予測 ・南アジア自家ワクチン市場：分析及び予測 … |
Autogenous Vaccines Market: Scope of the Report
Persistence Market Research (PMR) recently published a study on the global autogenous vaccines market. The study provides detailed assessment on key market dynamics, including the drivers, trends, opportunities restraints, and detailed information about the autogenous vaccines market structure. The market study presents exclusive information about how the autogenous vaccines market will grow during the forecast period of 2019-2029.
Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. Other information includes pricing analysis by region and by product type, which helps in deep understanding of the pricing details by researchers, suppliers, manufactures, and distributors. The other information contains volume analysis, which includes year wise growth of autogenous vaccines during the forecast period. This information can help readers understand the quantitative growth prospects of the autogenous vaccines market during the forecast period.
The study is relevant for manufacturers, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Business researcher, shareholders, industry experts can leverage the information and data presented in PMR’s study.
The study also includes statistics as well as facts related to macroeconomics factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the autogenous vaccines market. Furthermore, small businesses and new entrants in the autogenous vaccines market too can make use of the information presented in this study, based on which, they can make appropriate business decisions in order to gain momentum in the market.
Key Questions Answered in PMR’s Autogenous Vaccines Market Report
Which regions will continue to remain the most profitable regional markets for autogenous vaccines market players?
Which factors will induce a change in the demand for autogenous vaccines during the assessment period?
What are the different opportunities available for emerging players in the autogenous vaccines market?
How are supply-side and demand-side drivers impacting the autogenous vaccines market?
How will changing trends impact the autogenous vaccines market?
How can market players capture the low-hanging opportunities in the autogenous vaccines market in developed regions?
Which companies are leading the autogenous vaccines market?
What are the winning strategies of stakeholders in the autogenous vaccines market to upscale their position in this landscape?
Autogenous Vaccines Market: Research Methodology
In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the autogenous vaccines market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analyst ensure accuracy and reliability of conclusions.
Secondary resources referred to analyst during the production of the autogenous vaccines market study include statistics from government healthcare organizations, medicines journals, research journals, press release, annual reports, white papers, directories, and databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary resources and secondary resources acts as a validation from companies in the autogenous vaccines market, and makes PMR’s projection on the growth prospects of the autogenous vaccines market more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
4. Market Context
4.1. Regulatory Scenario
4.2. Parent Market Analysis
5. Global Autogenous Vaccines Market Demand (in Value or Size in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2029
5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018
5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
6. Market Background
6.1. Macro-Economic Factors
6.2. Forecast Factors – Relevance & Impact
6.3. Market Dynamics
6.3.1. Drivers
6.3.2. Restraints
6.3.3. Opportunity Analysis
7. Global Autogenous Vaccines Market Analysis 2014-2018 and Forecast 2019-2029, by Strain Type
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) & Volume (Mn Units) Analysis By Strain Type, 2014 – 2018
7.3. Current and Future Market Size (US$ Mn) & Volume (Mn Units) Analysis and Forecast By Strain Type, 2019 – 2029
7.3.1. Bacterial Strain
7.3.2. Virus Strain
7.4. Market Attractiveness Analysis By Strain Type
8. Global Autogenous Vaccines Market Analysis 2014-2018 and Forecast 2019-2029, by End User
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By End User, 2014 – 2018
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2019 – 2029
8.3.1. Veterinary Clinics
8.3.2. Veterinary Hospitals
8.3.3. Veterinary Research Institutes
8.4. Market Attractiveness Analysis By End User
9. Global Autogenous Vaccines Market Analysis 2014-2018 and Forecast 2019-2029, by Region
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Region, 2014 – 2018
9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019 – 2029
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. East Asia
9.3.5. South Asia
9.3.6. Oceania
9.3.7. Middle East & Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Autogenous Vaccines Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 – 2018
10.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 – 2029
10.3.1. By Country
10.3.1.1. U.S.
10.3.1.2. Canada
10.3.2. By Strain Type
10.3.3. By End User
10.4. Market Attractiveness Analysis
10.4.1. By Country
10.4.2. By Strain Type
10.4.3. By End User
11. Latin America Autogenous Vaccines Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 – 2018
11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 – 2029
11.3.1. By Country
11.3.1.1. Brazil
11.3.1.2. Mexico
11.3.1.3. Rest of Latin America
11.3.2. By Strain Type
11.3.3. By End User
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Strain Type
11.4.3. By End User
12. Europe Autogenous Vaccines Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 – 2018
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 – 2029
12.3.1. By Country
12.3.1.1. Germany
12.3.1.2. Italy
12.3.1.3. France
12.3.1.4. U.K.
12.3.1.5. Spain
12.3.1.6. BENELUX
12.3.1.7. Russia
12.3.1.8. Rest of Europe
12.3.2. By Strain Type
12.3.3. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Strain Type
12.4.3. By End User
13. South Asia Autogenous Vaccines Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 – 2018
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 – 2029
13.3.1. By Country
13.3.1.1. India
13.3.1.2. Thailand
13.3.1.3. Indonesia
13.3.1.4. Malaysia
13.3.1.5. Rest of South Asia
13.3.2. By Strain Type
13.3.3. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Strain Type
13.4.3. By End User
14. East Asia Autogenous Vaccines Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 – 2018
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 – 2029
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Strain Type
14.3.3. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Strain Type
14.4.3. By End User
15. Oceania Autogenous Vaccines Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 – 2018
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 – 2029
15.3.1. By Country
15.3.1.1. Australia
15.3.1.2. New Zealand
15.3.2. By Strain Type
15.3.3. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Strain Type
15.4.3. By End User
16. Middle East and Africa Autogenous Vaccines Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 – 2018
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 – 2029
16.3.1. By Country
16.3.1.1. GCC Countries
16.3.1.2. Turkey
16.3.1.3. Northern Africa
16.3.1.4. South Africa
16.3.1.5. Rest of Middle East and Africa
16.3.2. By Strain Type
16.3.3. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Strain Type
16.4.3. By End User
17. Emerging Countries Autogenous Vaccines Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029
17.1. Introduction
17.1.1. Market Value Proportion Analysis, By Key Countries
17.1.2. Global Vs. Country Growth Comparison
17.2. China Autogenous Vaccines Market Analysis
17.2.1. Introduction
17.2.2. Market Value Proportion Analysis by Market Taxonomy
17.2.3. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
17.2.3.1. By Strain Type
17.2.3.2. By End User
17.3. India Autogenous Vaccines Market Analysis
17.3.1. Introduction
17.3.2. Market Value Proportion Analysis by Market Taxonomy
17.3.3. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
17.3.3.1. By Strain Type
17.3.3.2. By End User
17.4. Brazil Autogenous Vaccines Market Analysis
17.4.1. Introduction
17.4.2. Market Value Proportion Analysis by Market Taxonomy
17.4.3. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
17.4.3.1. By Strain Type
17.4.3.2. By End User
18. Market Structure Analysis
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Deep Dive
19.2.1. Newport Laboratories, Inc. (Boehringer Ingelheim International GmbH)
19.2.1.1. Overview
19.2.1.2. Product Portfolio
19.2.1.3. Profitability by Market Segments (Product/Channel/Region)
19.2.1.4. Sales Footprint
19.2.1.5. Strategy Overview
19.2.1.5.1. Marketing Strategy
19.2.1.5.2. Product Strategy
19.2.1.5.3. Channel Strategy
19.2.2. Elanco Animal Health
19.2.2.1. Overview
19.2.2.2. Product Portfolio
19.2.2.3. Profitability by Market Segments (Product/Channel/Region)
19.2.2.4. Sales Footprint
19.2.2.5. Strategy Overview
19.2.2.5.1. Marketing Strategy
19.2.2.5.2. Product Strategy
19.2.2.5.3. Channel Strategy
19.2.3. Ceva (Ceva Biovac)
19.2.3.1. Overview
19.2.3.2. Product Portfolio
19.2.3.3. Profitability by Market Segments (Product/Channel/Region)
19.2.3.4. Sales Footprint
19.2.3.5. Strategy Overview
19.2.3.5.1. Marketing Strategy
19.2.3.5.2. Product Strategy
19.2.3.5.3. Channel Strategy
19.2.4. Cambridge Technologies
19.2.4.1. Overview
19.2.4.2. Product Portfolio
19.2.4.3. Profitability by Market Segments (Product/Channel/Region)
19.2.4.4. Sales Footprint
19.2.4.5. Strategy Overview
19.2.4.5.1. Marketing Strategy
19.2.4.5.2. Product Strategy
19.2.4.5.3. Channel Strategy
19.2.5. Hygieia Biological Laboratories
19.2.5.1. Overview
19.2.5.2. Product Portfolio
19.2.5.3. Profitability by Market Segments (Product/Channel/Region)
19.2.5.4. Sales Footprint
19.2.5.5. Strategy Overview
19.2.5.5.1. Marketing Strategy
19.2.5.5.2. Product Strategy
19.2.5.5.3. Channel Strategy
19.2.6. Dyntec s. r. o
19.2.6.1. Overview
19.2.6.2. Product Portfolio
19.2.6.3. Profitability by Market Segments (Product/Channel/Region)
19.2.6.4. Sales Footprint
19.2.6.5. Strategy Overview
19.2.6.5.1. Marketing Strategy
19.2.6.5.2. Product Strategy
19.2.6.5.3. Channel Strategy
19.2.7. Phibro Animal Health Corporation
19.2.7.1. Overview
19.2.7.2. Product Portfolio
19.2.7.3. Profitability by Market Segments (Product/Channel/Region)
19.2.7.4. Sales Footprint
19.2.7.5. Strategy Overview
19.2.7.5.1. Marketing Strategy
19.2.7.5.2. Product Strategy
19.2.7.5.3. Channel Strategy
19.2.8. Huvepharma, Inc.
19.2.8.1. Overview
19.2.8.2. Product Portfolio
19.2.8.3. Profitability by Market Segments (Product/Channel/Region)
19.2.8.4. Sales Footprint
19.2.8.5. Strategy Overview
19.2.8.5.1. Marketing Strategy
19.2.8.5.2. Product Strategy
19.2.8.5.3. Channel Strategy
19.2.9. Deltamune
19.2.9.1. Overview
19.2.9.2. Product Portfolio
19.2.9.3. Profitability by Market Segments (Product/Channel/Region)
19.2.9.4. Sales Footprint
19.2.9.5. Strategy Overview
19.2.9.5.1. Marketing Strategy
19.2.9.5.2. Product Strategy
19.2.9.5.3. Channel Strategy
19.2.10. AniCon Labor GmbH
19.2.10.1. Overview
19.2.10.2. Product Portfolio
19.2.10.3. Profitability by Market Segments (Product/Channel/Region)
19.2.10.4. Sales Footprint
19.2.10.5. Strategy Overview
19.2.10.5.1. Marketing Strategy
19.2.10.5.2. Product Strategy
19.2.10.5.3. Channel Strategy
19.2.11. ACE Laboratory Services (Apiam Animal Health)
19.2.11.1. Overview
19.2.11.2. Product Portfolio
19.2.11.3. Profitability by Market Segments (Product/Channel/Region)
19.2.11.4. Sales Footprint
19.2.11.5. Strategy Overview
19.2.11.5.1. Marketing Strategy
19.2.11.5.2. Product Strategy
19.2.11.5.3. Channel Strategy
20. Assumptions and Acronyms Used
21. Research Methodology
List of TableTable 01: Global Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Strain Type
Table 02: Global Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User
Table 03: Global Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Region
Table 04: North America Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country
Table 05: North America Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Strain Type
Table 06: North America Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User
Table 07: Latin America Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country
Table 08: Latin America Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Strain Type
Table 09: Latin America Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User
Table 10: Europe Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country
Table 11: Europe Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Strain Type
Table 12: Europe Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User
Table 13: South Asia Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country
Table 14: South Asia Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Strain Type
Table 15: South Asia Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User
Table 16: East Asia Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country
Table 17: East Asia Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Strain Type
Table 18: East Asia Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User
Table 19: Oceania Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country
Table 20: Oceania Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Strain Type
Table 21: Oceania Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User
Table 22: MEA Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country
Table 23: MEA Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Strain Type
Table 24: MEA Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User
Table 25: China Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Strain Type
Table 26: China Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User
Table 27: India Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Strain Type
Table 28: India Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User
Table 29: Brazil Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Strain Type
Table 30: Brazil Autogenous Vaccines Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User